A pediatric case of IgA nephropathy benefitting from targeted release formulation –budesonide

ConclusionOur case demonstrates that TRF-budesonide could be considered an effective second-line treatment in pediatric IgAN, particularly when a long course of steroids is necessary to control active inflammation. However, pediatric clinical trials to identify the correct dosage and tolerability of TRF-budesonide are urgently needed.
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research